Spots Global Cancer Trial Database for ovarian cancer stage iv
Every month we try and update this database with for ovarian cancer stage iv cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy | NCT05005650 | Ovarian Cancer ... Lymph Node Meta... | debulking surge... | 18 Years - 90 Years | Seoul National University Hospital | |
| Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer | NCT03693248 | Ovarian Cancer ... Ovarian Cancer ... Fallopian Tube ... Peritoneal Canc... | Two cycles of n... | 20 Years - 80 Years | Seoul National University Hospital | |
| Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer | NCT04701645 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Ovarian Cancer ... Ovarian Cancer ... Fallopian Tube ... Fallopian Tube ... | Microdevice | 18 Years - | Dana-Farber Cancer Institute | |
| PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . | NCT03275506 | Ovarian Cancer ... | Pembrolizumab I... Chemotherapy - ... | 18 Years - 75 Years | ARCAGY/ GINECO GROUP | |
| PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer | NCT05187208 | Epithelial Ovar... Ovarian Cancer Ovarian Cancer ... Ovarian Cancer ... | Niraparib | 20 Years - | Seoul National University Hospital | |
| Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | NCT06268665 | Breast Cancer Breast Cancer S... Breast Cancer S... Breast Cancer S... Breast Cancer S... Invasive Breast... Ovarian Cancer Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Breast Cancer S... Breast Cancer I... Breast Cancer, ... Breast Cancer, ... Breast Cancer S... Breast Cancer S... Breast Cancer S... Breast Cancer S... Cancer, Breast Tumors, Breast Mammary Cancer Mammary Carcino... Breast Carcinom... Breast Neoplasm Malignant Breas... Malignant Tumor... Cancer of Ovary Ovary Cancer Ovary Neoplasm | Tart Cherry Jui... | 18 Years - | University of California, Davis | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | NCT03126812 | Ovarian Cancer ... Peritoneal Canc... Fallopian Tube ... | Carboplatin Paclitaxel Pembrolizumab | 18 Years - | The Netherlands Cancer Institute | |
| Self-Advocacy Serious Game in Advanced Cancer | NCT03339765 | Ovarian Cancer ... Ovarian Cancer ... Breast Cancer S... Cervical Cancer... Cervical Cancer... Cervical Cancer... Endometrial Can... Endometrial Can... Vulvar Cancer, ... Vulvar Cancer, ... Vaginal Cancer ... Vaginal Cancer ... Vaginal Cancer ... | Strong Together... | 18 Years - | University of Pittsburgh | |
| A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) | NCT03899610 | Ovarian Cancer ... Ovarian Cancer ... | Neoadjuvant che... | 20 Years - | Yonsei University | |
| Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments | NCT06025045 | Ovarian Cancer ... Ovarian Cancer ... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | ||
| Tumor Microenvironment in Ovarian Cancer | NCT06272240 | Ovarian Cancer ... Ovarian Cancer ... | Ovarian Cancer ... | 18 Years - 80 Years | University of Udine | |
| Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer | NCT03085238 | Ovarian Cancer ... Ovarian Cancer ... | M-Trap | 18 Years - | MTrap, Inc. | |
| Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer | NCT03579394 | Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... | Retarded IDS (I... Standard IDS (I... | 18 Years - 99 Years | ARCAGY/ GINECO GROUP | |
| To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | NCT03159585 | Liver Cancer St... Gastric Cancer ... Esophageal Canc... Bone and Soft T... Breast Cancer S... Bladder Carcino... Prostate Carcin... Thyroid Cancer ... Ovarian Cancer ... Solid Tumor | TAEST16001 | 18 Years - 75 Years | Zhujiang Hospital | |
| Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer | NCT00945191 | Ovarian Cancer ... Ovarian Cancer ... | CS-1008 Paclitaxel Carboplatin | 18 Years - | Daiichi Sankyo | |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | NCT04938583 | Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... | Oregovomab Bevacizumab Paclitaxel Carboplatin | 19 Years - | CanariaBio Inc. | |
| A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | NCT05479045 | Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... | NY-ESO-1 Peptid... Nivolumab | 18 Years - | Georgetown University | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | NCT04938583 | Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... | Oregovomab Bevacizumab Paclitaxel Carboplatin | 19 Years - | CanariaBio Inc. | |
| PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . | NCT03275506 | Ovarian Cancer ... | Pembrolizumab I... Chemotherapy - ... | 18 Years - 75 Years | ARCAGY/ GINECO GROUP | |
| Prehabilitation in Gynaecological Cancer Patients | NCT04789694 | Ovarian Cancer Ovarian Cancer ... Ovarian Cancer ... Endometrial Can... Frailty | Physiological i... Psychological i... Nutritional int... | 18 Years - 85 Years | Charles University, Czech Republic | |
| Prehabilitation in Gynaecological Cancer Patients | NCT04789694 | Ovarian Cancer Ovarian Cancer ... Ovarian Cancer ... Endometrial Can... Frailty | Physiological i... Psychological i... Nutritional int... | 18 Years - 85 Years | Charles University, Czech Republic | |
| Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR) | NCT06017557 | Ovarian Cancer ... Ovarian Cancer ... | Artificial Inte... | 18 Years - | University Health Network, Toronto | |
| Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer | NCT03922776 | Ovarian Cancer ... Fallopian Tube ... Fallopian Tube ... Ovarian Cancer ... | Blood sample co... | 18 Years - | Centre Oscar Lambret | |
| Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy | NCT05005650 | Ovarian Cancer ... Lymph Node Meta... | debulking surge... | 18 Years - 90 Years | Seoul National University Hospital | |
| Tumor Microenvironment in Ovarian Cancer | NCT06272240 | Ovarian Cancer ... Ovarian Cancer ... | Ovarian Cancer ... | 18 Years - 80 Years | University of Udine | |
| Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR) | NCT06017557 | Ovarian Cancer ... Ovarian Cancer ... | Artificial Inte... | 18 Years - | University Health Network, Toronto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
